Our approach to cancer care has changed dramatically over the past decade. Treatment decisions once based only on tumor histology and disease stage can now be guided by precise molecular profiling and biomarker-driven insights. Advances in biomarker testing, assays and next-generation sequencing (NGS) platforms have created new avenues for precision medicine. Yet, even as the science accelerates, the integration of these innovations into everyday clinical practice lags.

Scientific discovery continues to accelerate, but its impact is limited by the pace of clinical implementation. Identifying what’s slowing translation and defining how we can close the gap from innovation to patient impact should be a central focus for the industry. The challenge lies in overcoming the distinct barriers that diagnostic innovations face on the path to clinical adoption, from evidence generation and regulatory approval to the day‑to‑day operational and reimbursement. The slow clinical adoption of these tools directly translates into missed testing, delayed treatment decisions and avoidable use of less effective standard therapies.

Companion diagnostics (CDx), positioned at the intersection of pathology, drug development, and patient access, have emerged as a critical bridge between diagnostic discovery and therapeutic access. CDx, leveraging next generation sequencing (NGS), are reshaping how targeted therapies are developed, brought to market, and delivered to patients.

To realize the potential of precision oncology, the focus must shift to accelerating the path from diagnostic to treatment by examining the systemic barriers, strengthening pharma–diagnostics co-development and improving diagnostic turnaround time.

Understanding the bottlenecks

New tools and technologies are advancing faster than healthcare systems can adopt, making it harder to determine which will truly move the needle for patients. Yet despite this progress, translating them from the research bench to the bedside remains slow and uneven.

Diagnostic innovations face three core barriers: generating evidence needed to support clinical and regulatory review, integrating tests into clinical workflows, and securing reimbursement.

Developing new biomarkers requires extensive evidence to establish clinical validity and utility, often through large-scale validation studies, prospective clinical trials and multi-center efforts. The process can be time-consuming and resource‑intensive; specifically for predictive biomarkers, it can take anywhere from five to ten years from discovery to widespread clinical adoption.

For new assays and technology platforms, a key barrier lies in moving from “research‑grade” experimentation to “clinical‑grade” reliability. Assays often begin in academic or specialized laboratories, handled by expert users operating with flexible protocols and minimal regulatory oversight. Transitioning these tools into routine clinical workflows across diverse lab settings requires standardized processes—validated protocols, automation, reproducibility, and rigorous analytical validation. In practice, this level of validation requires significant investment to achieve in vitro diagnostic (IVD) status and enable broad deployment.

Validated biomarkers and assays continue to face barriers integrating into clinical settings.

Implementation requires alignment across operational processes, such as test‑ordering, sample logistics, and turnaround times, to ensure results arrive before treatment decisions are made.

Behaviorally, adoption involves education and coordination across multidisciplinary teams including oncologists, pathologists, laboratory staff and administrators to ensure that new diagnostics are correctly ordered, processed and acted upon. Especially in community hospitals, where adoption gaps are largest, expanding the use of these tools are critical to reducing inequities in access to precision medicine.

The ultimate barrier that dictates the pace and scale of adoption continues to be reimbursement. Novel diagnostics face comprehensive evaluation cycles from insurers, who demand concrete evidence of clinical utility, cost‑effectiveness and patient outcome benefits before permitting coverage.

As alignment across payors, pharmaceutical companies, medical societies and regulators can take years, even clinically proven tests struggle to achieve broad use, trapping innovation in pilot programs or niche settings.

What results is a growing gap between innovation and the reality of what can be feasibly integrated into clinical practice. While precision medicine holds the tools to optimize cancer care, the industry will remain caught in a cycle of fragmented implementation until these translational bottlenecks are addressed, leaving patients with inconsistent access to the diagnostics that could meaningfully improve their outcomes.

Real-world impact of pharma-diagnostic collaborations

As the industry works to align access to precision oncology care with the pace of scientific innovation, collaboration has emerged as more than a competitive advantage, but a catalyst for patient impact. No single stakeholder, whether diagnostic developer, pharmaceutical company or healthcare provider can close the translation gap alone. The industry has shown that diagnostic companies need to evolve from being technology providers to becoming true clinical solution partners, enabling precision medicine to meet patients where they are.

Precision medicine cannot remain concentrated in academic medical centers; and needs to be brought directly to patients, and that means establishing broad accessibility. For diagnostic innovation to scale, it has to fit into standard clinical workflows through automated platforms that are easy to operate, are reproducible, and suitable for non‑expert users.

An FDA‑approved IVD platform can further reduce validation burden for hospitals, improving clinician confidence in test result interpretation, and streamlining reimbursement discussions with payers.

At the center of this shift is the convergence of CDx and NGS. Together, they are reshaping how clinicians identify actionable molecular targets, how therapies are developed and how quickly patients can access the treatments most aligned with their unique tumor biology. CDx and drug co‑development creates an integrated ecosystem where new therapies and corresponding biomarker tests are validated and approved in parallel, dramatically shortening the time from development to patient access.

When diagnostic and pharmaceutical pipelines move in sync, biomarker‑driven trials become more efficient, regulatory submissions can be coordinated and reimbursement pathways are clearer because the clinical utility is directly tied to an approved therapy. An experienced diagnostic partner with the ability to adapt to drug development changes, mitigate risks, and effectively manage regulatory feedback is essential for keeping the drug submission timeline on track. This means patients can be tested and treated immediately after a therapy approval, without waiting for companion test validation to catch up.

When working with a credible diagnostic partner with proven experience, this joint model also ensures that diagnostic innovation can seamlessly scale globally. Distributed IVD‑based CDx platforms can be adapted to local regulatory pathways, implemented across regional laboratory networks, and supported by appropriate training programs. This decentralization is critical to bringing precision oncology into routine care in markets where centralized testing models are less viable.

The success of these precision diagnostics don’t just depend on the sophistication of biomarkers and sequencing platforms, but on how effectively the industry works together to make them the available for every patient, in any setting.

Why turnaround time matters

For many patients facing a cancer diagnosis, time is precious and can be just as valuable a consideration as the treatment itself. Traditionally, laboratories relied on single-biomarker tests, but with the growing need for multiple biomarkers, sequential single-biomarker tests can cause delays and quickly use up valuable tissue, sometimes requiring a re-biopsy for the patient.

NGS-based CDx has changed the playing field by allowing the simultaneous analysis of multiple genetic mutations, rather than testing one biomarker at a time. With platforms now able to deliver results in as little as 24 hours, there is an opportunity to more immediately inform care decisions.

For pharmaceutical companies, this directly translates into faster patient identification, stronger trial enrollment and a reduced risk of patients being lost to suboptimal or competing treatment pathways before a matched therapy is reached.

Achieving this efficiency requires early coordination between pharmaceutical and diagnostics partners to stay in lockstep across the development and regulatory processes. Together, they can quickly address challenges, streamline validation and accelerate patient access.

When a patient's treatment trajectory can shift within days of a result, rapid turnaround time is no longer a platform feature but a measure of clinical impact.